Longeveron (LGVN) Gross Profit (QoQ) (2020 - 2026)
Longeveron (LGVN) Gross Profit (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Longeveron | 15.18 Bn | 15.16 Bn | 264,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.72% |
| Dec 31, 2025 | 105.60% |
| Sep 30, 2025 | -14.38% |
| Jun 30, 2025 | -46.91% |
| Mar 31, 2025 | -48.11% |
| Dec 31, 2024 | -22.29% |
| Sep 30, 2024 | 98.26% |
| Jun 30, 2024 | 4.56% |
| Mar 31, 2024 | 16,550.00% |
| Dec 31, 2023 | -103.70% |
| Sep 30, 2023 | -41.94% |
| Jun 30, 2023 | 22.37% |
| Mar 31, 2023 | 238.18% |
| Dec 31, 2022 | -159.78% |
| Sep 30, 2022 | -42.50% |
| Jun 30, 2022 | -3.03% |
| Mar 31, 2022 | 139.13% |
| Dec 31, 2021 | -57.93% |
| Sep 30, 2021 | -21.15% |
| Jun 30, 2021 | 39.60% |